[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-migraine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-migraine":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,84,112],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100610086","bilateral-embolization-of-the-middle-meningeal-arteries-for-refractory-chronic-migraine-100610086",false,"NCT07223008","Bilateral Embolization of the Middle Meningeal Arteries for Refractory Chronic Migraine","A Pilot Study of Safety and Feasibility of Bilateral Middle Meningeal Artery Embolization (bMMAE) in Patients With Refractory Chronic Migraine Headache: The MMAE-MIGRAINE Trial","MMAE-Migraine","Inclusion criteria:\n\n* Age 18\\\u003Cx\\\u003C80\n* Meets ICHD3 criteria for chronic migraine, (ICHD3, 1.3; with inclusion of ICHD3 1.1 and 1.2.1 only), with first migraine before age 50 (in concordance with previously published trials in migraine therapy36,39) . Patients must experience bilateral migraine symptoms.\n* Satisfy criteria for refractory chronic migraine defined as failure of, inadequate response to, or inability to tolerate migraine preventatives in at least 2 classes. Migraine preventatives include beta-blockers, calcium channel blockers, anti-convulsants (valproic acid, topiramate), anti-depressants (venlafaxine, amitriptyline), CGRP monoclonal antibodies, botulinum toxin injections. Chronic migraines must have persisted for at least 12 months prior to enrollment and at least 6 months after failing 2 classes of medication.\n* Has not used opiates or barbiturates as acute (rescue) therapy for migraine headache. Opiate or barbiturate use for reasons other than migraine is allowed. Other classes of acute migraine medications are acceptable. Acute (rescue, abortive) medications for migraines include acetaminophen, NSAIDs (ibuprofen, naproxen), gepants, triptans, anti-emetics (anti-nausea medications).\n* Exclusion of secondary headache disorder which may cause migraines\u002Fsymptoms, including MRI\u002FMRA (performed as routine care showing no underlying lesion that may be causing headaches, within 3 years of screening).\n* At least one migraine free day during the last month per headache diary.\n* Minimum MIDAS score of 21 (reflecting severely disabling migraine, in concordance with ongoing MMA lidocaine infusion trial44).\n* Able to read\u002Fwrite in English. Patients who are not English language users will not be enrolled as the study assessments are only validated in English.\n* Able to sign informed consent for themselves.\n* Able to complete study requirements\u002Ffollow-up as outlined in study plan section 3.6.\n\nExclusion criteria:\n\n* History of cranial or cervical vascular interventions or surgery, including craniotomy\u002Fcraniectomy, shunt placement, stereoelectroencephalography, and carotid endarterectomy.\n* A history of opiate or barbiturate use for the treatment of chronic migraine within one year.\n* Current intracranial lesions as determined by routine care MRI for exclusion of secondary headache disorders.\n* History of cranial radiation treatment.\n* Patients with additional diagnoses under ICHD3 (such as hemiplegic migraine, basilar migraine, new daily persistent headache, or cluster headache) are ineligible\n* Significant liver function impairment or serum creatinine \\> 2.0 mg\u002FdL. Patients with elevated creatinine levels who are on dialysis may be eligible.\n* History of systemic malignancy or auto-immune inflammatory disorders (such as multiple sclerosis, rheumatoid arthritis, autoimmune diseases).\n* History of life-threatening allergy to radiographic contrast. Patients with this allergy may be eligible if it can be managed medically.\n* Enrollment in another migraine study which could confound this study's endpoints, including undergoing any intervention or receiving an experimental drug under investigation for migraine therapy.\n* Additional medical or social concerns which could confound this study's endpoints or otherwise create undue risk or interfere with the participant's ability to complete the study, as assessed by the PI.\n* As this study is open only to patients with chronic migraine, which is refractory to treatment, patients who have previously been diagnosed with chronic migraine but now experience episodic migraine due to effective therapy are not eligible.\n* Patients with additional diagnoses under ICHD3 (such as hemiplegic migraine, basilar migraine, new daily persistent headache, or cluster headache) are ineligible.","ALL","18 Years","80 Years",{"count":21,"type":22},13,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study.\n\nParticipants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.",[28,29,30],"Migraine","Chronic Migraine Headache","Refractory Migraine",[32,33],"embolization","middle meningeal artery","RECRUITING","2026-04-28",{"date":37,"type":38},"2026-05-04","ACTUAL",{"date":40,"type":38},"2026-04-24",{"date":42,"type":22},"2028-04",{"name":44,"class":45},"Johns Hopkins University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":46},"100617067","embrace-study-enduring-migraine-benefit-from-responsive-artery-coil-embolization-100617067","NCT07313800","EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization","Enduring Migraine Benefit From Responsive Artery Coil Embolization (EMBRACE): A Single-Site, Non-Significant Risk Pilot Study of Middle Meningeal Artery Embolization Using FDA-Cleared Coils for Refractory Episodic Migraine","EMBRACE","Inclusion Criteria:\n\n* Age 18-60 years\n* Diagnosis of migraine (with or without aura)\n\n  -≥8 headache days per month\n* Failure of ≥2 preventive medication classes\n* Ability to complete electronic headache diary and surveys\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Secondary headache disorders\n* Prior MMA embolization\n* Contraindication to angiography or embolization\n* Pregnancy\n* Inability to comply with follow-up","60 Years",{"count":57,"type":22},25,[25],"This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).",[61,30,62],"Migraine Disorders","Chronic Migraine",[64,65,30,66,67,68,69,70,71,72],"Middle Meningeal Artery Embolization","MMA Embolization","Coil Embolization","Neurovascular Intervention","Migraine Prevention","TEMMA","TEMMA procedure","TEMMA protocol","Targeted Embolization for Migraine Management","NOT_YET_RECRUITING","2026-02-02",{"date":76,"type":38},"2026-02-04",{"date":78,"type":22},"2026-03-01",{"date":80,"type":22},"2028-03-01",{"name":82,"class":83},"Cortex Neurovascular","INDUSTRY",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":46},"100620740","phase-2-localized-injection-of-lidocaine-via-the-middle-meningeal-artery-for-intractable-headache-treatment-100620740","NCT07361549","Localized Injection of Lidocaine Via the Middle Meningeal Artery for Intractable Headache Treatment","Localized Injection of Lidocaine Via the Middle Meningeal Artery for Intractable Headache Treatment: A Randomized, Double-Blinded, Parallel Phase 2 Clinical Trial","LIGHT 2","Inclusion Criteria:\n\n* Age 18 years or above\n* Referred for diagnostic angiography\n* Diagnosis of intractable migraine\n* Written informed consent able to be obtained from subject\n\nExclusion Criteria:\n\n* Baseline HIT-6 score less than 60 (severe)\n* Pregnant, breastfeeding, or unwilling to practice contraception during participation in the study\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data\n* Concomitant intracranial pathology (eg, intracranial malignancy)\n* Known hypersensitivity and\u002For contraindication to lidocaine or local anesthetics of the amide type\n* Taking chronic medications that, when co-administered with lidocaine and other local anesthetics, are at increased risk of developing methemoglobinemia (nitrates\u002Fnitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, acetaminophen, metoclopramide, quinine, sulfasalazine)\n* Known contraindications for angiography (eg, ESRD not requiring hemodialysis). Patients with contrast allergy with be premeditated with diphenhydramine and steroids.\n* Contraindication to anesthetic agents used for conscious sedation\u002Fmonitored anesthesia care (MAC)\n* Concurrent participation in another research protocol for investigation of an experimental therapy\n* Per DSA imaging, presence of a cerebrovascular pathology known to cause headache (eg, arteriovenous malformation, dural arteriovenous fistula)\n* Per DSA imaging, presence of anastomosis or anatomical variation (eg, branches of middle meningeal artery) that could lead to increased procedural risk\n* Per DSA imaging, lack of endovascular access to either middle meningeal artery, or origin of the middle meningeal artery other than from the external carotid artery\n* Known or suspected inability to adhere to study protocol or protocol requirements, as per discretion of the Investigator or treating provider",{"count":93,"type":22},80,[95],"PHASE2","The goal of this clinical trial is to test whether injecting lidocaine into two blood vessels of the brain can help treat chronic headaches (migraines)",[30,98],"Headache",[100,101,102,33],"headache","migraine","lidocaine","2026-01-21",{"date":105,"type":38},"2026-01-23",{"date":107,"type":22},"2026-03",{"date":109,"type":22},"2031-07",{"name":111,"class":45},"Daniel A Tonetti, MD",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":4},"100599683","occipital-nerve-stimulation-in-chronic-migraine-100599683","NCT07087678","Occipital Nerve Stimulation in Chronic Migraine","A Prospective, Randomised, Open Label Feasibility Trial Comparing BurstDR Microdosing Versus Tonic Occipital Nerve Stimulation for Patients With Refractory Chronic Migraine","Inclusion Criteria:\n\nAge ≥ 18 years old and diagnosed with intractable chronic migraine by a headache specialist, as defined by the International Classification of Headache Disorders-3 (ICHD-3).\n\nSubject should have failed to gain benefit from at least 4 classes of oral preventative medications, Botulinum toxin or acupuncture as defined by NHS (National Health Service) England Subject has been diagnosed at least 6 months prior to study enrolment with migraine headache with or without aura according to the ICHD-3 criteria 1.1, 1.2.1, or 1.3.\n\nSubject is able to distinguish migraine attacks from other headaches (e.g. tension type headache, cluster headaches).\n\nSubject agrees to not participate in supplemental or alternative therapy through the Follow Up Period of the study. This includes acupuncture, spinal manipulation, TENS (transcutaneous electrical nerve stimulation), and magnetic fields treatments.\n\nSubject has the ability to read, comprehend, and to reliably record information as required by the Protocol.\n\nSubject is able to provide written informed consent prior to participation in the study.\n\nExclusion Criteria:\n\nSubject's overall health, age and\u002For comorbidities place subject at high risk for complications from surgery and\u002For general anaesthesia.\n\nSubject has clinically significant drug (including opioid) or alcohol abuse as defined by DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision), will likely be unable to refrain from substance abuse throughout the study, has another significant pain problem, substance abuse or active depressive episode that might confound the study assessments in the opinion of the Investigator.\n\nSubject is currently participating or has participated in the last month in another clinical study in which the subject has, is, or will be exposed to, an investigational drug or device, except for sponsor-related studies.\n\nSubject is felt to be at risk of non-compliance (e.g., for completing the diary\u002Fquestionnaires or returning for required follow-up visits) in the Investigator's opinion.\n\nSubject has medication overuse headache which has not been managed (by withdrawal of the causative medication).\n\nSubject is a woman of childbearing potential who is pregnant, nursing, or not using effective contraception.\n\nSubject has an active implantable device such as pacemaker\u002F defibrillator or other neurostimulation device.\n\nSubject has a history of bleeding disorders or coagulopathy or is unable to discontinue anticoagulation, antiplatelet, or GP (glycoprotein) IIb IIIa inhibitor medication in preparation for the implantation procedure.\n\nSubject is not suitable for the study for any reason in the judgment of the Investigator.",{"count":120,"type":22},40,[25],"The goal of this clinical trial is to compare two different types of occipital nerve stimulation (BurstDR (dorsal root) microdosing versus Tonic) in chronic refractory migraine. The main questions it aims to answer is whether BurstDR microdosing is effective in reducing moderate to severe headache days compared to Tonic stimulation (which is currently in use). Additionally, the safety of both types of stimulation will be studied.\n\nParticipants will be asked to keep a headache diary, then have the device implanted and programmed, and keep a subsequent headache diary to see if there is an improvement in their headaches after three moths of stimulation. If they don't respond to treatment, they will be allowed to swap to the other type of stimulation to see if this improves their symptoms.",[124,30],"Chronic Migraine, Headache",[126,127,128,129],"Chronic migraine","Occipital nerve stimulation","BurstDR microdosing","Refractory migraine","2025-07-18",{"date":132,"type":38},"2025-07-28",{"date":134,"type":22},"2025-09-01",{"date":136,"type":22},"2028-06-01",{"name":138,"class":45},"University College, London"]